AU2016362683B2 - Treatment of cancer with a PI3K inhibitor in a patient preselected for having a PIK3CA mutation in the ctDNA - Google Patents

Treatment of cancer with a PI3K inhibitor in a patient preselected for having a PIK3CA mutation in the ctDNA Download PDF

Info

Publication number
AU2016362683B2
AU2016362683B2 AU2016362683A AU2016362683A AU2016362683B2 AU 2016362683 B2 AU2016362683 B2 AU 2016362683B2 AU 2016362683 A AU2016362683 A AU 2016362683A AU 2016362683 A AU2016362683 A AU 2016362683A AU 2016362683 B2 AU2016362683 B2 AU 2016362683B2
Authority
AU
Australia
Prior art keywords
cancer
patient
ctdna
amide
pik3ca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016362683A
Other languages
English (en)
Other versions
AU2016362683A1 (en
Inventor
Emmanuelle DI TOMASO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2016362683A1 publication Critical patent/AU2016362683A1/en
Application granted granted Critical
Publication of AU2016362683B2 publication Critical patent/AU2016362683B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016362683A 2015-12-03 2016-11-30 Treatment of cancer with a PI3K inhibitor in a patient preselected for having a PIK3CA mutation in the ctDNA Ceased AU2016362683B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262620P 2015-12-03 2015-12-03
US62/262,620 2015-12-03
PCT/IB2016/057208 WO2017093905A1 (en) 2015-12-03 2016-11-30 Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna

Publications (2)

Publication Number Publication Date
AU2016362683A1 AU2016362683A1 (en) 2018-05-31
AU2016362683B2 true AU2016362683B2 (en) 2019-11-07

Family

ID=57517943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016362683A Ceased AU2016362683B2 (en) 2015-12-03 2016-11-30 Treatment of cancer with a PI3K inhibitor in a patient preselected for having a PIK3CA mutation in the ctDNA

Country Status (13)

Country Link
US (2) US20180353515A1 (https=)
EP (1) EP3383391A1 (https=)
JP (1) JP2018535997A (https=)
KR (1) KR20180084830A (https=)
CN (1) CN108366998A (https=)
AU (1) AU2016362683B2 (https=)
CA (1) CA3006419A1 (https=)
HK (1) HK1253737A1 (https=)
IL (1) IL259716A (https=)
MX (1) MX2018006777A (https=)
RU (1) RU2018123524A (https=)
TW (1) TW201722429A (https=)
WO (1) WO2017093905A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355545A1 (en) * 2018-10-15 2021-11-18 The Johns Hopkins University Methods and materials for assessing and treating cancer
CN116240287A (zh) * 2023-01-17 2023-06-09 普洱市人民医院 基于循环肿瘤dna的乳腺癌标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013144249A1 (en) * 2012-03-29 2013-10-03 Novartis Ag Pharmaceutical diagnostic
WO2015172085A2 (en) * 2014-05-09 2015-11-12 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641809B2 (en) 2003-07-05 2018-10-03 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
SI3296407T1 (sl) 2004-03-02 2019-09-30 The Johns Hopkins University Mutacije gena PIK3CA pri rakih pri ljudeh
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013144249A1 (en) * 2012-03-29 2013-10-03 Novartis Ag Pharmaceutical diagnostic
WO2015172085A2 (en) * 2014-05-09 2015-11-12 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C. FRITSCH ET AL, "Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials", MOLECULAR CANCER THERAPEUTICS, (2014), vol. 13, no. 5, pages 1117 - 1129 *
CHIYA OSHIRO ET AL, "PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients", BREAST CANCER RESEARCH AND TREATMENT., US, (2015-03-04), vol. 150, no. 2, p 299 - 307 *
CRISTIAN MASSACESI ET AL, "Overcoming Phosphatidylinositol 3-Kinase (PI3K) Activation in Breast Cancer: Emerging PI3K Inhibitors", THE JOURNAL OF ONCOPATHOLOGY, (2015-02-01), vol. 3, no. 1, p 27 - 39 *
Dejan Juric ET AL, "Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study", Cancer Research AACR 103rd Annual Meeting Abstracts, (2012), p1-3 *
JOHAN F. VANSTEENKISTE ET AL, "Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer", JOURNAL OF THORACIC ONCOLOGY (2015)v10p1319 - 1327 *
Payal D. Shah ET AL, "Abstract PD5-3: Phase I trial: PI3K[alpha] inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)", Cancer Research, (2015-05-01), pages 1 - 4, *

Also Published As

Publication number Publication date
CA3006419A1 (en) 2017-06-08
CN108366998A (zh) 2018-08-03
MX2018006777A (es) 2018-08-01
US20180353515A1 (en) 2018-12-13
IL259716A (en) 2018-07-31
TW201722429A (zh) 2017-07-01
AU2016362683A1 (en) 2018-05-31
RU2018123524A3 (https=) 2020-04-02
JP2018535997A (ja) 2018-12-06
US20200138824A1 (en) 2020-05-07
KR20180084830A (ko) 2018-07-25
EP3383391A1 (en) 2018-10-10
RU2018123524A (ru) 2020-01-09
WO2017093905A1 (en) 2017-06-08
HK1253737A1 (zh) 2019-06-28

Similar Documents

Publication Publication Date Title
Remon et al. Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
Canaparo et al. Expression of CYP3A isoforms and P‐glycoprotein in human stomach, jejunum and ileum
Kennedy et al. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making
Bordi et al. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
KR20140012137A (ko) Hr 양성 대상체에서의 유방암용 바이오마커로서의 fgfr 및 이의 리간드
US11685953B2 (en) Biomarkers and methods of treating cancer
US11208690B2 (en) Prognostic assay for squamous cell lung carcinoma
BRPI0214821B1 (pt) Método para determinar a responsividade de indivíduo com distúrbio psicótico ao tratamento com loperidona
Locatelli et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia
Malapelle et al. Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
Conca et al. Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib
US20200138824A1 (en) Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
Toppmeyer et al. Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
US20200370118A1 (en) Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss)
WO2012103060A1 (en) Method of administration and treatment
US20230160016A1 (en) Methods of selecting a treatment for cancer patients
AU2008286407A1 (en) Predictive markers for EGFR inhibitor treatment
JP2008526775A (ja) 慢性便秘の患者におけるテガセロドの有効性を同定するためのバイオマーカー
Motzer et al. Germline genetic biomarkers of sunitinib efficacy in advanced renal cell carcinoma: results from the RENAL EFFECT trial
JP2012508019A (ja) Ａｂｌチロシンキナーゼ阻害剤による慢性骨髄性白血病の治療の最適化方法
Seddon et al. Let us know how access to this document benefits you.
WO2025080726A1 (en) Methods of treating conditions with mutant p53 reactivating compounds
WO2013043130A1 (en) Method and/or probe for determining glaucoma susceptibility and/or predicting/detecting shallow anterior chamber depth
IL203647A (en) Predictive marker for egfr inhibitor treatment
Kulkarni et al. Imatinib mesylate resistance and mutations: An Indian experience

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired